MedTrace Logo

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

NCT04750824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.

Conditions

  • Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG

Afatinib

Afatinib

DRUG

other systemic therapy

other systemic therapy

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-12-20
Completion
2021-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750824 on ClinicalTrials.gov